Navigation Links
Kensey Nash Reports Second Quarter Fiscal Year 2011 Financial Results
Date:2/1/2011

U.S. and outside the U.S.  However, due to the significant cost and risk of obtaining U.S. regulatory approval with the uncertain U.S. regulatory climate, restrictive clinical requirements, protracted patient enrollment and extended follow up timeframe for the Company's cartilage technology in the U.S., the Company is shifting its clinical activities for the cartilage product outside the U.S.  The Company plans to reallocate its research and development funds towards products with more predictable near term regulatory approval criteria.

The Company currently expects that its operating margin will be approximately 33% in fiscal 2011 and its balance sheet will continue to be strengthened by adding cash from operations for the full fiscal year of approximately $20 million (excluding any in-process R&D charges and acquisition costs related to Nerites).

The Company is currently estimating that third quarter fiscal 2011 total revenues will be in the range of $18.5 to $19.0 million. Net sales are currently expected to be in the range of $11.7 to $12.1 million, and royalties are currently expected to be in the range of $6.8 to $6.9 million.  The Company currently expects third quarter fiscal 2011 diluted earnings per share of $0.42 to $0.44 (excluding any in-process R&D charges and acquisition costs related to Nerites).  

Stock Repurchase Update. During the six months ended December 31, 2010, the Company repurchased 1,175,738 shares of Common Stock, at a total cost of approximately $30.0 million, or an average market price of $25.52 per share, using available cash.  This completed the latest $30 million repurchase program.  The Company had 8,523,360 shares of Common Stock outstanding as of December 31, 2010.  

Income taxes.  The Company currently estimates that its fiscal 2011 effective tax rate will be between 32% and 33%.  In the course of estimating the Company's annual eff
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
3. Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
4. Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
5. Kensey Nash to Present at the 2009 UBS Global Life Sciences Conference
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Target Underlying Defect in Cystic Fibrosis; CFTR ... ... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it ... covering compounds demonstrated to improve cystic,fibrosis transmembrane conductance regulator (CFTR) ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... will begin,immediately. Fentanyl Transdermal System is ... in 25, 50, 75 and 100 mcg/hour ...
... HUNTSVILLE, Ala., Aug. 22 DNA2.0,Inc. ... synthetic genes, and,Operon Biotechnologies (http://www.operon.com ), ... formation of a partnership to utilize their,synergistic ... Operon,s oligonucleotide production platform with DNA2.0,s,gene synthesis ...
Cached Biology Technology:BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 2BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 3BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 4Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2
(Date:7/23/2014)... are crucial for providing essential fatty acids and ... feeding. There has been concern that soybean-based emulsions ... due to its composition. Combination lipid emulsions based ... have been developed to address this concern. , ... that concern may be unwarranted, according to a ...
(Date:7/22/2014)... of both still images and video of artistic ... Forty-four still images were chosen from more than ... and alumni representing more than 25 different University ... 50 submissions. , Zach Donnell, a graduate student ... organizers, noted that the exhibit highlights the interplay ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... years ago Mark Kay, MD, PhD, published the first ... RNA interference was an effective gene-therapy technique in mice. ... flurry amongst both academic and industry research groups. , ... way, Kay's initial excitement is proving to be on ...
... phones excite the brain cortex adjacent to it, ... other neurological conditions. This finding is published in ... & Sons. The article is also available online ... million people in the world use cell phones ...
... as Ritalin to quell symptoms of attention deficit hyperactivity ... drugs work in the brain. , But new work ... clear up some of the mystery. Writing in the ... primarily target the prefrontal cortex (PFC), a region of ...
Cached Biology News:For Stanford scientists, RNAi gene therapy takes two steps forward, one step back 2Cell phone emissions excite the brain cortex 2Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... pending) was developed using a protein engineering approach ... binding pocket of wild-type DNase I. These changes ... DNA. The result is a versatile enzyme that ... an ability to maintain at least 50% of ...
Rabbit polyclonal to hnRNP-U...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
Biology Products: